EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression

Arun Satelli, Izhar Batth, Zachary Brownlee, Abhishek Mitra, Shouhao Zhou, Hyangsoon Noh, Christina R. Rojas, Heming Li, Qing H. Meng, Shulin Li

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs. To address this gap in technology, we recently discovered the utility of cellsurface vimentin (CSV) as a marker for detecting mesenchymal CTCs from sarcoma, breast, and colon cancer. Here we studied peripheral blood samples of 48 prostate cancer (PCA) patients including hormone sensitive and castration resistant sub-groups. Blood samples were analyzed for three different properties including our own CSVbased CTC enumeration (using 84-1 mAb against CSV), CellSearch-based epithelial CTC counts, and serum prostate-specific antigen (PSA) quantification. Our data demonstrated that in comparison with CellSearch, the CSV-based method had greater sensitivity and specificity. Further, we observed significantly greater numbers of CTCs in castration resistant patients as measured by our CSV method but not CellSearch. Our data suggests CSV-guided CTC enumeration may hold prognostic value and should be further validated as a possible measurement of PCA progression towards the deadly, androgen-independent form.

Original languageEnglish (US)
Pages (from-to)49329-49337
Number of pages9
JournalOncotarget
Volume8
Issue number30
DOIs
StatePublished - Jan 1 2017

Fingerprint

Circulating Neoplastic Cells
Vimentin
Prostatic Neoplasms
Castration
Epithelial Cells
Prostate-Specific Antigen
Tumor Biomarkers
Sarcoma
Colonic Neoplasms
Androgens
Cell Count
Hormones
Breast Neoplasms
Technology
Biopsy
Sensitivity and Specificity
Serum

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Satelli, Arun ; Batth, Izhar ; Brownlee, Zachary ; Mitra, Abhishek ; Zhou, Shouhao ; Noh, Hyangsoon ; Rojas, Christina R. ; Li, Heming ; Meng, Qing H. ; Li, Shulin. / EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. In: Oncotarget. 2017 ; Vol. 8, No. 30. pp. 49329-49337.
@article{e9f7796f008942b8b911900a30b8ebea,
title = "EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression",
abstract = "Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs. To address this gap in technology, we recently discovered the utility of cellsurface vimentin (CSV) as a marker for detecting mesenchymal CTCs from sarcoma, breast, and colon cancer. Here we studied peripheral blood samples of 48 prostate cancer (PCA) patients including hormone sensitive and castration resistant sub-groups. Blood samples were analyzed for three different properties including our own CSVbased CTC enumeration (using 84-1 mAb against CSV), CellSearch-based epithelial CTC counts, and serum prostate-specific antigen (PSA) quantification. Our data demonstrated that in comparison with CellSearch, the CSV-based method had greater sensitivity and specificity. Further, we observed significantly greater numbers of CTCs in castration resistant patients as measured by our CSV method but not CellSearch. Our data suggests CSV-guided CTC enumeration may hold prognostic value and should be further validated as a possible measurement of PCA progression towards the deadly, androgen-independent form.",
author = "Arun Satelli and Izhar Batth and Zachary Brownlee and Abhishek Mitra and Shouhao Zhou and Hyangsoon Noh and Rojas, {Christina R.} and Heming Li and Meng, {Qing H.} and Shulin Li",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.17632",
language = "English (US)",
volume = "8",
pages = "49329--49337",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "30",

}

Satelli, A, Batth, I, Brownlee, Z, Mitra, A, Zhou, S, Noh, H, Rojas, CR, Li, H, Meng, QH & Li, S 2017, 'EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression', Oncotarget, vol. 8, no. 30, pp. 49329-49337. https://doi.org/10.18632/oncotarget.17632

EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. / Satelli, Arun; Batth, Izhar; Brownlee, Zachary; Mitra, Abhishek; Zhou, Shouhao; Noh, Hyangsoon; Rojas, Christina R.; Li, Heming; Meng, Qing H.; Li, Shulin.

In: Oncotarget, Vol. 8, No. 30, 01.01.2017, p. 49329-49337.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression

AU - Satelli, Arun

AU - Batth, Izhar

AU - Brownlee, Zachary

AU - Mitra, Abhishek

AU - Zhou, Shouhao

AU - Noh, Hyangsoon

AU - Rojas, Christina R.

AU - Li, Heming

AU - Meng, Qing H.

AU - Li, Shulin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs. To address this gap in technology, we recently discovered the utility of cellsurface vimentin (CSV) as a marker for detecting mesenchymal CTCs from sarcoma, breast, and colon cancer. Here we studied peripheral blood samples of 48 prostate cancer (PCA) patients including hormone sensitive and castration resistant sub-groups. Blood samples were analyzed for three different properties including our own CSVbased CTC enumeration (using 84-1 mAb against CSV), CellSearch-based epithelial CTC counts, and serum prostate-specific antigen (PSA) quantification. Our data demonstrated that in comparison with CellSearch, the CSV-based method had greater sensitivity and specificity. Further, we observed significantly greater numbers of CTCs in castration resistant patients as measured by our CSV method but not CellSearch. Our data suggests CSV-guided CTC enumeration may hold prognostic value and should be further validated as a possible measurement of PCA progression towards the deadly, androgen-independent form.

AB - Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs. To address this gap in technology, we recently discovered the utility of cellsurface vimentin (CSV) as a marker for detecting mesenchymal CTCs from sarcoma, breast, and colon cancer. Here we studied peripheral blood samples of 48 prostate cancer (PCA) patients including hormone sensitive and castration resistant sub-groups. Blood samples were analyzed for three different properties including our own CSVbased CTC enumeration (using 84-1 mAb against CSV), CellSearch-based epithelial CTC counts, and serum prostate-specific antigen (PSA) quantification. Our data demonstrated that in comparison with CellSearch, the CSV-based method had greater sensitivity and specificity. Further, we observed significantly greater numbers of CTCs in castration resistant patients as measured by our CSV method but not CellSearch. Our data suggests CSV-guided CTC enumeration may hold prognostic value and should be further validated as a possible measurement of PCA progression towards the deadly, androgen-independent form.

UR - http://www.scopus.com/inward/record.url?scp=85025807619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025807619&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17632

DO - 10.18632/oncotarget.17632

M3 - Article

VL - 8

SP - 49329

EP - 49337

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -